Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm

NCT02595866 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02595866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02595866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
April 4, 2016
Completion date
March 25, 2024
Enrollment
58 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

aids-related non-hodgkin lymphoma, clinical stage iii cutaneous melanoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, hepatocellular carcinoma, hiv infection, kaposi sarcoma, locally advanced lung non-small cell carcinoma, locally advanced malignant solid neoplasm, metastatic lung non-small cell carcinoma, metastatic malignant solid neoplasm, metastatic melanoma, non-hodgkin lymphoma, recurrent classic hodgkin lymphoma, recurrent malignant neoplasm, refractory classic hodgkin lymphoma, refractory malignant neoplasm, stage iii lung cancer ajcc v8, stage iv lung cancer ajcc v8, unresectable melanoma